miss angiosarcoma broader
develop also halt downgrad neutral
tracon termin phase tappa trial plu votrient
advanc metastat angiosarcoma futil follow dsmb review
unblind interim data patient enrol time
analysi result tracon termin enrol tracon-
sponsor trial oncolog tracon expect cash extend
oncolog indic repres materi portion
npv prior analysi oper remov
potenti materi catalyst partnership move
sidelin downgrad tcon share neutral
disappoint result remain
encourag tracon recent partnership china-bas i-mab
antibodi broad bispecif antibodi
develop effort enter clinic quarter first
bispecif program enter clinic fda recent clear
tracon ind antibodi advanc solid
tumor phase focu biomark assess potenti
enrich later studi initi data could manifest
like addit tracon on-going partnership
santen wet janssen prostat
cancer read meaning phase data
tracon target addit clinic program run
data upcom tracon opportun wet
depend upon phase data due due
increas sampl size trial phase prostat cancer data
could present materi phase data
tracon materi econom tie success
assess valuat compani util npv methodolog
much lower materi asset term
valuat far elimin pipelin
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
tracon background/descript diversifi
clinic stage biopharmaceut compani found headquart
san diego develop novel target therapeut variou cancer
wet age-rel macular degener diseas leader
develop therapeut util endoglin biolog essenti escap
pathway vegf inhibit mechan therapeut wide use
block angiogenesi format new blood vessel oncolog wet
novel anti-endoglin antibodi phase develop
wet ophthalm partner santen tracon retain materi
tracon differenti drug develop busi model given
materi experi oncolog therapeut develop led
util contract research organ conduct
studi make clinic develop much effici addit aid
develop compani becom develop entiti
program potenti bolster pipelin result compani
recent materi success approach engag janssen
rate develop collabor two promis molecul discuss
manag also util expertis area oncolog engag
nation cancer institut nci gain support assist
conduct number studi second proprietari
interact
santen collabor wet could provid upsid earli phase
studi evalu singl dose ophthalm formul
appar success move phase
combin anti-vegf therapi wet patient refractori
anti-vegf therapi initi data phase studi present
novemb februari show potenti show
signal efficaci vegf-refractori popul addit solid
base excis repair inhibitor announc phase data glioblastoma
current phase develop mesothelioma well earli trial
solid tumor trial sponsor nation cancer institut
bind intermedi base excis repair pathway revers
acquir resist certain type chemotherapi potenti
complement activ poli adp-ribos polymeras parp inhibitor
inhibit pathway also allow resist alkyl
chemotherapi temodar
temozolomid antimetabolit
chemotherapi alimta pemetrex data readout phase
studi could lead materi upsid tcon share separ
molecul target endoglin version activ
preclin model nash consid develop fibrosi
set target endoglin set appear revers fibrosi
tracon announc strateg licens develop collabor
janssen oncolog two oncolog asset million equiti
invest potenti item view transact
underscor compani abil obtain non-dilut capit broaden
pipelin also valid tracon clinic develop capabl
advanc molecul pan-androgen receptor antagonist
prostat cancer potenti overcom resist exist
therapi inhibit wild type wt clinic relev ligand
bind domain mutant androgen receptor includ
point mutat phase trial determin maximum toler dose
initi studi trial patient
metastat castration-resist prostat cancer primari object
studi assess safeti determin recommend phase
dose assess respons prostate-specif antigen level biomark
circul tumor dna test also examin phase androgen
receptor inhibitor progressor data phase phase expect
respect earli data repres major potenti
valuat inflect point molecul also tracon recent
present data emerg first-in-class preclin asset novel
develop tracon return right janssen februari
tracon announc partnership china-bas i-mab biopharma
broaden tracon pipelin novel program add anoth
layer industri valid drug develop expertis i-mab deal
includ novel antibodi novel bi-specif antibodi
tracon lead clinic develop program north america
fund earli phase trial parti share cost advanc
develop commerci tracon share north american
right select bi-specif right in-licens certain
region expect begin dose advanc solid tumor patient
first bispecif program expect move clinic
develop
tracon recent upcom potenti catalyst
begin pivot studi angiosarcoma tracon
initi tappa global pivot trial spa
votrient patient angiosarcoma earli promis
indic pursu result durabl improv
compar vegf inhibitor seen combin earli phase
studi see detail
feb avastin effect gbm tracon announc
combin avastin rhhbi rate
improv median versu singl agent avastin recurr gbm patient
although combin associ non-signific increas
overal surviv consid gbm indic one higher
risk program
data phase wet santen top-line
data phase pave trial refractori wet patient
partner santen present novemb american academi
ophthalmolog meet greater detail present
angiogenesi exud degener meet februari
result demonstr activ improv
central retin subfield thick cst suggest
bioactiv patient wet refractori vegf
inhibitor result studi led santen pursu
robust phase avant studi wet also result
million mileston tracon
present nexavar data januari
asco gastrointestin cancer symposium nexavar
bayr rate show partial respons patient two
eight reduct alpha fetoprotein occur three
eight nexavar singl agent demonstr orr
phase trial recist respons appear gener
compar preliminari orr seen previous top
dose nexavar data appear support
nexavar combin popul
phase combo data gbm dna base
excis repair ber pathway inhibitor phase data present
societi neuro-oncolog sno meet announc nov
combin temozolomid patient
recurr glioblastoma combin show respons
studi though two patient demonstr evid materi
benefit remain aliv month patient
express n-methylpurin dna glycosylas biomark initi
base excis repair pathway resist inhibit
partnership china-bas i-mab biopharma broaden tracon
pipelin novel program add anoth layer industri
valid drug develop expertis i-mab deal includ
novel antibodi novel bi-specif antibodi tracon
lead clinic develop program north america na
fund earli phase trial parti share cost advanc
develop commerci tracon share na right
select bi-specif right in-licens certain region
data rcc decemb tracon announc top line
data traxar trial random phase ii trial compar
inlyta rate vs inlyta alon patient line metastat
clear cell renal cell carcinoma rcc trial demonstr
meaning activ rcc set addit biomark
analysi also demonstr addit benefit
earli activ opdivo combo tracon announc
encourag earli data phase trial nsclc
well toler dlt seen six patient one
six whose tumor express receiv prior
therapi reach pr remain studi month
five patient remain stabl diseas tracon enrol
patient parallel expans cohort includ
relaps naiv trial incorpor tumor biopsi test
determin correl tumor myeloid cell infiltr
respons enabl potenti biomarker-direct therapi lung cancer
patient data expans cohort expect late
ind file antibodi tracon
submit ind patient advanc solid tumor
decemb antibodi i-mab privat
develop partnership tracon includ
multipl immuno-oncolog program i-mab io portfolio initi
data could manifest
move phase prostat cancer tracon
advanc novel androgen receptor mutant inhibitor
phase portion phase studi studi enrol began
tracon expect phase data present
medic meet initi safeti data could lead meaning inflect
point recognit janssen collabor program phase data
expect posit data could trigger buy-
janssen
phase data data on-going phase
trial patient combin nexavar present
gi includ orr recist tracon expect complet
enrol onto phase portion assess orr low singl
agent respons nexavar set provid materi
room data meaning catalyst program
tracon report initi data pivot tappa trial
votrient angiosarcoma studi stop futil tracon
also announc plan termin compani sponsor trial
regulatori fda health agenc oversight compani whose
main busi drug develop tracon subject rigor
strenuou regulatori requir us food drug administr
fda intern medicin develop regulatori agenc
new drug approv market promot approv drug
product also regul fda relat agenc throughout globe
though compani specif focu ethic prescript pharmaceut
place signific risk oper believ risk time
greater less research-bas drug develop
compani biotechnology/biopharmaceut industri
manufactur fda oversight fda quit vigil inspect
drug biolog manufactur plant us global tracon
and/or contract manufactur could therefor subject risk fda
regard manufactur meaning problem tracon
manufactur oper could materi potenti product
consequ could materi neg affect tracon
oper tcon share
potenti increment revenu driven corpor partner portion
tracon revenu expect profit growth could achiev
mileston royalti compani may receiv collabor
janssen santen possibl other road tracon provid
develop expertis janssen collabor santen
deal howev tracon may control final sale product
expect compani continu aggress pursu
develop sale respect program though
assur compani behav manner would
benefit econom paid tracon
continu develop stabl in-hous proprietari program investor
like place greater emphasi success program
assur tracon success effort develop
program particular oncolog use
fibrosi failur develop proprietari pipelin time even slower
progress expect pipelin develop could result
neg pressur place upon tcon share
reimburs risk patient physician insur may ascertain
benefit valu tracon brand therapeut benefici light
particular insur could requir rigor requir prior author
payment prescript approv manag care
significantli accept tracon product price arrang compani
revenu could insuffici obtain profit tcon sharehold
could experi neg return result
financi risk compani unabl obtain licensur us
addit intern market product unabl suffici
differenti compar gener brand option
indic pursu materi addit dilut exist sharehold
possibl investor percept tcon share could substanti
risk tracon parti collabor signific
agreement contain complex commerci term could result
disput litig indemnif liabil could advers affect
busi result financi condit addit tracon number
studi conduct nih guarante agenc
oper continu manner materi benefici
tracon tcon sharehold could materi harm result
except per share revenue- growth product revenue- total us sale rcc lung eu/row royalti milestones- total revenu goodsresearch market promot interest expens incom expens fair valu prefer stock fair valu prefer incom tax provisionnet profit accret redempt valu redeem convert prefer loss attribut common tracon compani report sec file btig research estimatesrobert bert hazlettbtigoffic tcon incom statement
btig cover compani mention report
appendix analyst certif import disclosur
